Literature DB >> 15939190

Mechanisms of sarcomagenesis.

Igor Matushansky1, Robert G Maki.   

Abstract

Sarcomas comprise a heterogeneous group of malignancies that are derived from mesenchymal cells, which under normal circumstances lead to the development of connective tissues such as bone, muscle, fat, and cartilage. During the past decade, insight has been gained regarding the aberrancies that occur during normal development that result in mesenchymal cells transforming into sarcomas. More recently, these insights have led to the development of successful therapies that target the specific mechanisms inherent to individual sarcomas. This overview discusses some of the aberrant molecular mechanisms shared in sarcomas and reviews several sarcoma subtypes in which the most advances have been made. Finally, the ways in which these advances in basic science are translating into and redefining clinical practice are highlighted.

Entities:  

Mesh:

Year:  2005        PMID: 15939190     DOI: 10.1016/j.hoc.2005.03.006

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

1.  Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.

Authors:  Joslyn Mills; Todd Hricik; Sara Siddiqi; Igor Matushansky
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

2.  Targeting sarcoma tumor-initiating cells through differentiation therapy.

Authors:  Dan Han; Veronica Rodriguez-Bravo; Elizabeth Charytonowicz; Elizabeth Demicco; Josep Domingo-Domenech; Robert G Maki; Carlos Cordon-Cardo
Journal:  Stem Cell Res       Date:  2017-04-13       Impact factor: 2.020

3.  Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo.

Authors:  Joslyn Mills; Tulio Matos; Elizabeth Charytonowicz; Todd Hricik; Mireia Castillo-Martin; Fabrizio Remotti; Francis Y Lee; Igor Matushansky
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

Review 4.  MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century.

Authors:  Igor Matushansky; Elizabeth Charytonowicz; Joslyn Mills; Sara Siddiqi; Todd Hricik; Carlos Cordon-Cardo
Journal:  Expert Rev Anticancer Ther       Date:  2009-08       Impact factor: 4.512

5.  Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2.

Authors:  Rosario Gil-Benso; Javier Megías; Teresa San-Miguel; Sandra Pinto; Robert C Callaghan; Concha López-Ginés; Miguel Cerdá-Nicolás
Journal:  Cytotechnology       Date:  2017-07-04       Impact factor: 2.058

6.  The T-box transcription factor 3 is a promising biomarker and a key regulator of the oncogenic phenotype of a diverse range of sarcoma subtypes.

Authors:  T Willmer; A Cooper; D Sims; D Govender; S Prince
Journal:  Oncogenesis       Date:  2016-02-22       Impact factor: 7.485

Review 7.  Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.

Authors:  Akshay D Baheti; Jyothi P Jagannathan; Ailbhe O'Neill; Harika Tirumani; Sree Harsha Tirumani
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

8.  Elucidating potentially significant genomic regions involved in the initiation and progression of undifferentiated pleomorphic sarcoma.

Authors:  Paul Kurywchak; Jeff Kiefer; Elizabeth Lenkiewicz; Lisa Evers; Tara Holley; Michael Barrett; Glen J Weiss
Journal:  Rare Tumors       Date:  2013-03-25

Review 9.  Managing sarcoma: where have we come from and where are we going?

Authors:  Jenna S Bleloch; Reyna D Ballim; Serah Kimani; Jeannette Parkes; Eugenio Panieri; Tarryn Willmer; Sharon Prince
Journal:  Ther Adv Med Oncol       Date:  2017-09-20       Impact factor: 8.168

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.